cutaneous squamous cell carcinoma

The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. With interim results from a pivotal clinical trial of its lead PD-L1 checkpoint inhibitor incoming, biotech firm Checkpoint Therapeutics (...